Why Zogenix, Inc. Was a House of Pain for Investors
Did the FDA just give the green light to a dangerous drug from Zogenix?
Why Zogenix Inc. Shares Swooned
Zogenix shares falter after the company reports disappointing fourth-quarter results. Find out what investors should really have their eyes on instead.
Zogenix Stockholders Facing World of Pain?
The share price of Zogenix has soared more than 260% during the past year, driven by investor optimism for new opioid painkiller Zyhydro ER. Will the drug be a commercial success?
Acetaminophen: 4 Things to Know About This Common Over-the-Counter Drug
The FDA recently issued a warning regarding liver damage caused by acetaminophen. Here are four things consumers and investors need to know about the drug, and how it could affect companies like Johnson & Johnson, Novartis, GlaxoSmithKline, and Zogenix.
3 Key Stocks To Watch Today: Illumina, Inc., Allergan, Inc., and Teva Pharmaceutical
Illumina, Allergan, and Teva could loom large in health care headlines this morning. Here's what you need to know.
Zogenix, Zohydro ER Face Familiar Post-Approval Hurdles
In a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...
Zogenix: 3 Key Investing Takeaways From 2013
Let’s take a look at 3 key investing takeaways from Zogenix’s volatile year, and how other companies, like Mallinckrodt, Valeant, and Teva fit into the company’s growth prospects for 2014.